BUCHANG PHARMA(SH:603858) Cai Fu Zai Xian·2026-02-10 07:30Core Viewpoint - The company, Buchang Pharma, emphasizes steady operations and innovative development while maintaining a strong commitment to shareholder returns and social responsibility, showcasing a clear blueprint for high-quality growth [1][2][4][5]. Shareholder Returns - Buchang Pharma has established a dual return mechanism of "dividends + buybacks," with cumulative dividends reaching 7.948 billion yuan and share buybacks totaling 1.744 billion yuan, significantly exceeding the IPO fundraising amount of 3.9 billion yuan [2]. - In 2022, the company distributed cash dividends of 1.062 billion yuan and completed share buybacks worth 934 million yuan, while in 2025, it increased buybacks by acquiring 6.6206 million shares for nearly 100 million yuan [2]. - The first buyback plan in 2026 involved repurchasing 2.176 million shares at a price significantly lower than the upper limit, demonstrating efficient capital management [2]. Social Responsibility - Buchang Pharma integrates social responsibility into its corporate DNA, supporting the "Together, Build a Chinese Heart" public welfare initiative, which has organized 32,000 volunteers and provided free surgeries for over 3,800 children with congenital heart disease [3]. - The company has contributed nearly 33 billion yuan in taxes since its establishment, playing a vital role in local economic development and rural revitalization [3]. Business Fundamentals - The company has a strong business foundation, focusing on major diseases like cardiovascular issues, with over 170 products included in the 2025 National Medical Insurance Directory [4]. - Buchang Pharma is expanding into biopharmaceuticals and chemical drugs, with its first Class 1 new drug expected to fill a market gap, and multiple innovative cancer drugs in critical clinical stages [4]. International Strategy - The company is deepening its international strategy through "product registration + international cooperation," successfully registering several products in countries like Malaysia and Canada [5]. - Buchang Pharma's products are now sold in dozens of countries, and strategic partnerships with companies in Malaysia and Russia are enhancing its global market penetration [5].